Both are still in trials but 10 months with chemotherapy versus 2.4 months could bring the drug to the front view of the public, as has been done in the past with activists groups pushing for approval of other drugs. Both are different with treatment plans and the drugs would be limited to the...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
12-04-2008
Filed under:
Filed under: Medically Related, Pharma/FDA News, healthcare, Pharma, Cancer, clinical trials, Prostate Cancer, PSA, R and D, antigen, testosterone
The National Cancer Institute has made clinical trial participation a top national priority and yet participant levels are still not perhaps where they could be. Yes, this is a big decision for any patient/physician to make as far as whether or not to enroll, but many trials are offering lifesaving...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
11-02-2008
Filed under:
Filed under: Medically Related, Pharma/FDA News, My Commentaries, Investors, health insurance, Pharma, Cancer, clinical trials, HMO, Pharmaceuticals, R and D, Drug Development, Cancer Institute
It is here but evolving slower than what all of us might like to see, and in many areas it is still so much of a “Science” but as developments occur through biotech we are seeing some amazing results. There’s also the bridging of the gap with bringing genomics to the point of care, as physicians...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
10-26-2008
Filed under:
Filed under: Medically Related, Technology, Pharma/FDA News, personalized medicine, healthcare, Pharma, Biotech, Cancer, tumors, Genentech, Herceptin, cancer vaccine
The UK continues to say “no” to cancer drugs due to price. If you stop and look at the prices for cancer drugs, something along the line here is going to need to balance soon. It is great and wonderful to have the R and D and great breakthroughs that are occurring almost daily, but what good does...
As the article states, you don’t need marketing for cancer drugs, as the need is unfortunately already there, thus marketing for cancer drugs does not necessarily carry the same sales expense as do other drugs. We have all seen the “tiered plans” on what level drugs are listed with insurance coverage...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
10-13-2008
Filed under:
Filed under: Medically Related, Insurance, Other Items of Interest, My Commentaries, personalized medicine, Genomics, health insurance, Pharma, Prescriptions, Cancer, R and D, Science 2.0
In other words, this is called Business Intelligence. Lots of it out there to choose from and one from Microsoft specifically related to hospital management and budgets. Before the demise of Wall Street it wasn’t too long ago that I posted about the All Nighter they pulled to mine and try...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
09-26-2008
Filed under:
Filed under: Medically Related, Technology, Other Items of Interest, My Commentaries, Pharma, Biotech, Cancer, Business Intelligence, R and D, Wall Street, Pricing
This is probably a good move to speed this process up since many pharmaceutical companies have and are looking at moving more trials to India. More information can be read here about the changing face of Pharma in reference to research and development. One more area to think about too is the use...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
09-19-2008
Filed under:
Filed under: Medically Related, Pharma/FDA News, Genomics, drugs, Pharma, Cancer, clinical trials, Congress, DNA Testing, National Cancer Institute, Justice Department
Many of the generic manufacturers started years back with knock off drugs to sell locally in India, but now the game is changing to where US Pharma is using some of the talent, which costs less than R and D individuals here in the states, to further develop existing work, in other words somewhat continue...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
09-05-2008
Filed under:
Filed under: Medically Related, Pharma/FDA News, Genomics, drugs, Pharma, Biotech, Cancer, FDA, Budgets, R and D, Alzheimers, Outsourcing
Right now according to the Wall Street Journal, patients who have enjoyed an open relationship are worried that this could all change under management from Roche. Is bigger always better? Recently in the news Genentech is not happy with the offer and may hold out for more. Anyone that...
The patent is stated not to expire until 2010 and this will put a 30 hold at the FDA to grant approval. This one should prove interesting to follow and see where the infringement occurs. BD LONDON -(Dow Jones)- Sanofi-Aventis SA (SNY) has launched a legal action against Canadian generic drugmaker...